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Among the messages of this simulation model for the UK and other countries is the 
resilience of hepatitis C in the face of considerable investment in methadone and needle 
exchange services, that these have nevertheless helped and need to be maintained and if 
possible expanded, but also that further measures are required to substantially curtail 
the virus.
Summary A simulation model for the UK and other countries was used to estimate the 
impact on the spread of hepatitis C virus of scaling-up opiate substitution therapy and 
high coverage needle and syringe programmes. 
Data which fed in to the simulation derived from a synthesis of results from UK studies 
published since the year 2000 which related use of these services to hepatitis C infection 
among injectors outside prison. Six studies were found. Two directly assessed the 
incidence of new infections by retesting injectors a year later. The other four took 
measurements at a single point in time, but used a laboratory test to identify which 
injectors were relatively newly infected. In the repeat-test studies, injectors were 
considered to have been in opiate substitution treatment if this occupied at least six of 
the 12 months of the follow-up period. For the remaining studies the definition was being 
in treatment at the time of the test for infection. Injectors were considered to be 'highly 
covered' by needle and syringe programmes if these had supplied them at least enough 
injecting equipment to have used a fresh set for each injection.
The conclusion was that when injectors were protected by one or other type of service to 
the degree set by the synthesis study, the chances of their becoming infected were 
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halved relative to the risk faced by injectors who had not adequately participated in 
either type of service. When injectors were protected by both, their risk of infection was 
just a fifth of that faced by injectors who had used neither to the degree set by the 
study, and this time the risk reduction was statistically significant.
These values were incorporated in the featured simulation study as the risk reduction 
effect of being in substitute prescribing and/or receiving enough sterile equipment for 
each injection in the past month. Data from GPs supported the assumption that on 
average patients stayed in treatment for eight months. In the absence of adequate data, 
the same assumption was made for high-coverage needle and syringe provision. The 
simulation was run for the UK specifically and for countries in general, varying the 
proportion of injectors engaged in either or both types of programmes. At issue was the 
effect of increasing these proportions, simulating the impact of scaling up service 
provision.
Main findings
The all-countries simulation assumed a baseline of no injectors receiving either type of 
service, and either 20%, 40% or 60% chronically infected with hepatitis C. As long as 
sustained for at least 15 years, recruiting 6 in 10 injectors in to adequate injecting 
equipment provision and substitute prescribing treatment was calculated to reduce the 
proportion infected with hepatitis C by a third. If just 4 in 10 were recruited, this degree 
of reduction would take 20 years. In the short-term the starting proportion infected made 
little difference, but over 20 years the interventions had less impact if introduced when a 
very high proportion of injectors were already infected. Varying assumptions about the 
effectiveness of the interventions was calculated to make a big difference to their impacts 
on the epidemics.
For the UK, data supported the assumed baseline of 40% of injectors chronically infected 
with hepatitis C and half of all injectors engaged in either opiate substitute prescribing 
programmes or high-coverage needle and syringe provision. The simulation extrapolated 
back to a hypothetical zero access to substitute prescribing and adequate needle 
exchange, leading to an estimate that assumed current service coverage of 50% may 
have reduced what would have been a 65% infection rate among injectors to 40%.
It was calculated that over the long term, recruiting just another 10% (up from 50% to 
60%) of UK injectors to these programmes would result in modest further reductions in 
infection rate, but that substantial progress would require scaling up these interventions 
so that both reach not half the injectors, but at least 8 in 10. This level sustained for 10 
years meant the infection rate would drop from 40% to 30%, and for 20 years, to about 
20%. Achieving increased coverage means recruiting more injectors to these 
programmes and/or retaining those who do use them for longer. Without increased 
retention, the recruitment rate has to be much higher. For example, at eight months 
retention, to get 8 in 10 injectors in to these programmes requires over half those not 
yet attending to join each month. If retention doubles to 16 months, then just under 
30% need to join each month – still over twice the assumed 12.5% baseline, but a more 
achievable figure.
Again, varying assumptions about the effectiveness of the interventions was calculated to 
make a big difference to their impacts on the infection rate. Even more influential was 
varying assumptions about what proportion of injectors stop injecting each year from 5% 
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up to 20%; interventions have greater impact the shorter the typical injecting career.
The authors' conclusions
This analysis suggests that opiate substitution therapy and high coverage needle and 
syringe programmes can reduce the prevalence of hepatitis C among injectors, but also 
that reductions are frequently modest and require many years of sustained intervention 
coverage. For instance, cutting prevalence by a third over 10 years would usually require 
over 60% of injectors to be engaged in these programmes. Projections for countries 
which already have sustained high coverage (such as the UK and Australia) suggest that 
many infections have been averted. For example, without such interventions 65% of UK 
injectors would have been chronically infected with hepatitis C, amounting to 50,000 
extra infections in England and Wales. But further substantial reductions (down by over 
half) are unlikely unless both interventions can be scaled-up to reach not 50%, but over 
80% of injectors for at least 20 years.
In the face of inadequate progress in curtailing hepatitis C, broadly one may recommend 
extending existing interventions to more injectors, or argue that this will not be enough 
and other interventions are required. Among these may be vaccination if this becomes 
available, treating infection, promoting ways to take drugs other than injecting, or 
distributing less transmission-prone equipment such as low dead space syringes.
Where conventional substitute and equipment supply programmes already reach a high 
proportion of injectors, the featured simulation suggests that additional alternative 
measures are indeed required to make substantial further progress. Only a very 
ambitious programme, for example recruiting 30% of injectors per month to these 
interventions and typically retaining them for 16 months, would see hepatitis C 
prevalence in nations such as the United Kingdom halved within 20 years. Such an 
expansion is unlikely to be sustained or funded. In contrast, where substitute prescribing 
and equipment supply programmes currently reach few injectors, initial efforts should 
focus on scaling up both interventions. In the long term, however, even in these areas 
other interventions such as treating infected patients will also be needed to substantially 
reduce the prevalence of hepatitis C. 
 The simulation illustrates why a country such as the UK which started with a 
high level of hepatitis C infection still has high levels despite considerable investment in 
needle exchange and methadone and buprenorphine maintenance. Without this 
investment, tens of thousands more people would have had their lives blighted by 
infection, but reducing this number by much more still would require a degree of 
commitment on the part both of injectors and health service funders which seems 
unlikely.
Sustaining and if possible increasing engagement in needle exchange and methadone 
and buprenorphine maintenance programmes is essential not just to contain hepatitis C, 
but also HIV, and for reasons not to do with infection control at all, but more will be 
needed. One clue to what comes from the study's finding that decreasing the length of 
injecting careers – which in itself would reduce the number of infections – also augments 
the impact of the interventions. If recovery-oriented national polices in Britain do work, 
the result should indeed be to curtail drug use and injecting careers. It has also recently 
become apparent that injecting is falling out of favour, another way in which infection 
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could be reduced and service coverage increased without extra resources. These 
comments are expanded on below.
Sophisticated as they are, the calculations made by the featured analysis depend on an association between 
infection rates and adequate needle exchange and substitute prescribing which could have been due to other 
factors. Conceivably, for example, injectors concerned and stable enough to stay in treatment and to make 
regular use of needle exchanges would have found other ways to avoid infection, even if exchanges and 
treatment were unavailable. In this scenario, it would not be the services which were active ingredients, but the 
characteristics of the injectors who tended to use them most. It should also be remembered that one half of the 
intervention duo modelled in the study – opiate substitute prescribing – is applicable only to patients addicted 
to these types of drugs. If sustained over many years, injecting crack increased the infection rate in the 
featured model, and the more primary crack injectors there are, the lower the proportion of injectors who might 
be attracted in to, accepted by, and retained by opiate substitute prescribing programmes.
High coverage is the key but can it be achieved?
An important finding from the study is that the effectiveness of maintenance and needle 
exchange in preventing infection is a major influence on how many injectors become 
infected. Not just sustaining and extending but also optimising both services is important. 
As emphasised by Findings in a series of reviews on hepatitis C and needle exchange, 
this and other bodies of work stress that the best way to curb the spread of HIV and 
hepatitis C among injectors is high coverage supply of injecting equipment, enough and 
sufficiently easily available for a fresh set to be used each time, allied with high coverage 
substitute prescribing.
However, complete coverage in terms of the supply of injecting equipment is very far 
from the norm in Britain, with the result that at the end of the first decade of the 2000s 
hepatitis C was spreading more rapidly than in the early 2000s, infecting a quarter of 
injectors within three years of their starting to inject.
Given funding constraints and the current policy emphasis on recovery from addiction 
and abstinence rather than harm reduction, it may be unrealistic to expect a further 
major contribution to stemming the hepatitis C epidemic from services intended to 
ameliorate damage from continued injecting. What would help is if their workload could 
be reduced because (aided or not by treatment) drug users themselves turn away from 
injecting, by far the most important route for infection. From population estimates and 
trends in the treatment caseload, it seems this may be happening, an estimated 137,000 
injecting drug users in England in 2004–05 falling to 117,000 in 2006–07.
NICE's verdict and other studies
The type of models exemplified by the featured analysis make estimates based on what 
ought to happen given current knowledge and best guesses, rather than what has 
actually happened. They have large margins for error in themselves and also because 
what they predict may not happen in reality. Also they form a limited basis for 
determining health policy because they do not extend to estimating whether spending on 
syringe distribution and prescribing programmes might save/improve more lives if used 
in another health sector entirely. However, within the limited remit of preventing 
infections among injectors, these programmes take pride of place, especially when opiate-
type drugs account for a major part of injecting.
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Despite the uncertainties, the results of such simulations, and those of studies of what 
actually happens, were enough to convince Britain's National Institute for Health and 
Clinical Excellence (NICE) that commissioners should aim to provide every injector with 
all the equipment they need to use a sterile set each time, the definition of high coverage 
in the featured analysis. The NICE committee reached these conclusions partly on the 
basis of a cost-effectiveness analysis. It concluded that extending adequate needle 
exchange to a higher proportion of injectors would usually save and improve lives at well 
below the cost to the health service normally considered to justify the expenditure. Also 
like the featured analysis, this work suggested that while increasing the coverage of 
syringe distribution and substitute prescribing programmes is sufficient to control HIV, it 
will not on its own substantially reduce hepatitis C infection; this requires a multi-faceted 
programme, including for example these interventions plus treatment of patients already 
infected with hepatitis C.
The featured study's results for Britain are likely to be broadly applicable to countries such as Australia with 
similar policies, services, drug use patterns and rates of HIV and hepatitis C infection, and vice versa. As in the 
featured analysis for Britain and hepatitis C, a recent simulation for Australia estimated that without needle and 
syringe distribution programmes, in 2000–2010 there would have been many more HIV and hepatitis C 
infections. Distribution programmes had it was calculated prevented 192–873 HIV infections (34–70% of what 
would have been the total) and 19,000–77,000 hepatitis C infections (15–43% of what would have been the 
total).
Unlike the featured analysis, the Australian study went on to estimate that needle and syringe distribution 
programmes were a highly cost-effective way to extend and improve lives by preventing infection-related 
illnesses including AIDS and liver disease. Also, cumulative costs savings over the life of injectors who would 
otherwise have been infected was estimated to mean that eventually each dollar spent on these programmes in 
2000–2010 would have saved from 1.3 to 5.5 times as much in averted healthcare costs.
Turning to opioid substitute prescribing, a systematic review of its impact on HIV concluded that this treatment 
reduces drug-related behaviours with a high risk of HIV transmission. Four studies assessed relationships 
between the proportions of people who actually became HIV positive (seroconversion) and their participation in 
methadone treatment. All found that participation as such, or more extended or continuous participation, was 
associated with a lower rate of seroconversion. However, impacts on hepatitis C are much less well established. 
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